Comparative Evaluation of Therapeutic Efficacy of Oral Tranexamic Acid versus its Intradermal Administration in Melasma – A Quasi-Experimental Study

Asma Malik; Muhammad Farhan Shahid; Muhammad Khurram Ahmad; Noman Khadam; Tayyaba Manzoor

doi:10.51253/pafmj.v76iSUPPL-2.12881

Authors

Asma Malik Department of Dermatology, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Pakistan
Muhammad Farhan Shahid Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Pakistan
Muhammad Khurram Ahmad Department of Dermatology, Combined Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Noman Khadam Department of Dermatology, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Pakistan
Tayyaba Manzoor Department of Dermatology, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS) Pakistan

DOI:

https://doi.org/10.51253/pafmj.v76iSUPPL-2.12881

Keywords:

Hyperpigmentation, Intradermal Injection, Melasma, Skin Pigmentation, Tranexamic Acid

Abstract

Objective: To compare the therapeutic efficacy of oral tranexamic acid versus transdermal tranexamic acid administration in patients with melasma.

Study Design: Quasi-experimental study.

Place and Duration of Study: Department of Dermatology, Pak Emirates Military Hospital (PEMH), Rawalpindi Pakistan, May to Oct 2024.

Methodology: The study enrolled 104 patients with diagnosed melasma, who were divided in a 1:1 ratio into two groups, Group A and Group B. Informed consent was taken from all patients. Group A received intralesional tranexamic acid while Group B took oral tranexamic acid 250mg twice a day. Modified Melasma Area and Severity Index (mMASI) was calculated for each patient at baseline and monitoring of both groups was done on a monthly basis with mMASI for 3 months.

Results: The median age of this sample was 35.22±9.83 years, comprising 95(91.30%) females and 9(8.70%) males. Median baseline mMASI for Group A was 18.6(5.85) and for Group B, it was also 18.6(5.85). Comparison from baseline mMASI score showed a consistent reduction in mMASI scores at each follow-up (p=0.00). In our study population, 49(94.23%) patients in the intralesional group responded to treatment, whereas 47(90.38%) patients responded to treatment in the oral tranexamic acid group (p=0.72).

Conclusion: Both routes of tranexamic acid administration demonstrated high response rates with np statistically significant differences.

Downloads

Download data is not yet available.

References

1. Kwon SH, Hwang YJ, Lee SK, Park KC. Heterogeneous pathology of melasma and its clinical implications. Int J Mol Sci 2016; 17(6): 824. https://doi.org/10.3390/ijms17060824

2. Grimes P, Kelly AP, Torok H, Willis I. Community-based trial of a triple-combination agent for the treatment of facial melasma. Cutis 2006; 77(3): 177–184.

https://pubmed.ncbi.nlm.nih.gov/16610738/

3. Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol 2006; 156(Suppl 1): 21–28.

https://doi.org/10.1111/j.1365-2133.2006.07590.x

4. Ortonne JP, Arellano I, Berneburg M, Cestari T, Chan H, Grimes P, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. J Eur Acad Dermatol Venereol 2009; 23(11): 1254–1262.

https://doi.org/10.1111/j.1468-3083.2009.03295.x

5. Noh TK, Choi SJ, Chung BY, Kang JS, Lee JH, Lee MW, et al. Inflammatory features of melasma lesions in Asian skin. J Dermatol 2014; 41(9): 788–794.

https://doi.org/10.1111/1346-8138.12573

6. Basit H, Godse KV, Al Aboud AM. Melasma. In: StatPearls [Internet]. StatPearls Publishing; 2024. Available from:

http://www.ncbi.nlm.nih.gov/books/NBK459271/

7. Platsidaki E, Efstathiou V, Markantoni V, Kouris A, Kontochristopoulos G, Nikolaidou E, et al. Self-esteem, depression, anxiety and quality of life in patients with melasma living in a sunny Mediterranean area: results from a prospective cross-sectional study. Dermatol Ther (Heidelb) 2023; 13(5): 1127–1136. https://doi.org/10.1007/s13555-023-00915-1

8. Rodrigues M, Ayala-Cortés AS, Rodríguez-Arámbula A, Hynan LS, Pandya AG. Interpretability of the modified melasma area and severity index (mMASI). JAMA Dermatol 2016; 152(9): 1051–1052. https://doi.org/10.1001/jamadermatol.2016.1429

9. Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Ther (Heidelb) 2017; 7(3): 305–318. https://doi.org/10.1007/s13555-017-0194-1

10. Zhang L, Tan WQ, Fang QQ, Zhao WY, Zhao QM, Gao J, et al. Tranexamic acid for adults with melasma: a systematic review and meta-analysis. Biomed Res Int 2018; 1683414.

https://doi.org/10.1155/2018/1683414

11. Khurana VK, Misri RR, Agarwal S, Thole AV, Kumar S, Anand T. A randomized, open-label, comparative study of oral tranexamic acid and tranexamic acid microinjections in patients with melasma. Indian J Dermatol Venereol Leprol 2019; 85(1): 39–43. https://doi.org/10.4103/ijdvl.IJDVL_801_16

12. Na JI, Choi SY, Yang SH, Choi HR, Kang HY, Park KC. Effect of tranexamic acid on melasma: a clinical trial with histological evaluation. J Eur Acad Dermatol Venereol 2013; 27(8): 1035–1039. https://doi.org/10.1111/j.1468-3083.2012.04464.x

13. Batra J, Brar BK, Kumar S, Arora H. Tranexamic acid in melasma: comparative evaluation of therapeutic efficacy of oral tranexamic acid versus its trans epidermal administration. J Cutan Aesthet Surg 2022; 15(4): 394–399.

https://doi.org/10.4103/JCAS.JCAS_237_20

14. Sharma R, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Shiny TN. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol 2017; 42(7): 728–734.

https://doi.org/10.1111/ced.13164

15. Shetty V, Shetty M. Comparative study of localised intradermal microinjection of tranexamic acid and oral tranexamic acid for the treatment of melasma. Int J Res Dermatol 2018; 4(3): 363–367.

https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20183159

16. Panchal VS, Patel YS, Dalal YD, Parikh AP, Dalal AD, Rana DA. Efficacy of oral, topical, and intradermal tranexamic acid in patients with melasma — a meta-analysis. Indian Dermatol Online J 2024; 15(1): 55–62.

https://doi.org/10.4103/idoj.idoj_495_22

17. Liang R, Luo H, Pan W, Yang S, Peng X, Kuang B, et al. Comparative efficacy and safety of tranexamic acid for melasma by different administration methods: a systematic review and network meta-analysis. J Cosmet Dermatol 2024; 23(3): 1150–1164. https://doi.org/10.1111/jocd.16104

18. Agrawal M, Varma K, Kumar U, Bhargava S, Mahadik A, Agrawal V. Comparison of oral versus topical tranexamic acid for treatment of melasma. IP Indian J Clin Exp Dermatol 2023; 9(1): 84–89.

https://doi.org/10.18231/j.ijced.2023.015